You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物-B(06185.HK):單劑Ad5-nCoV在18歲及以上健康成年人中安全有效
格隆匯 12-24 08:32

格隆匯12月24日丨康希諾生物-B(06185.HK)發佈公吿,公司注意到“柳葉刀”發佈一篇題為“單劑重組新型冠狀病毒疫苗(5型腺病毒載體)在18歲及以上成年人中的最終有效性分析、期中安全性分析及免疫原性:一項國際多中心、隨機、雙盲、安慰劑對照的III期試驗”的研究論文,內容有關公司重組新型冠狀病毒疫苗(5型腺病毒載體)(“Ad5-nCoV”, 商品名稱為克威莎)III期臨牀試驗的研究結果。

公吿稱,全球多中心III期臨牀試驗的終期分析結果顯示,單劑Ad5-nCoV在接種28天后對預防有症狀的COVID-19疾病顯示出57.5%的有效性,對預防重症疾病顯示出91.7%的有效性;在接種14天后對預防有症狀的COVID-19疾病顯示出63.7%的有效性,對預防重症疾病顯示出96.0%的有效性。Ad5-nCoV的保護率達到世界衞生組織設置的相關技術標準。在主要安全性分析中,在試驗參與者中沒有發生任何與疫苗相關的嚴重不良事件或死亡案例。單劑Ad5-nCoV在18歲及以上健康成年人中安全有效。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account